Rosetta Genomics to be acquired by Genoptix for $10M in cash
Genoptix and Rosetta Genomics (ROSG) jointly announced on Friday that they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a total gross purchase price of $10M.
After deducting expected payments for outstanding debt, convertible debentures, warrant termination payments, professional fees, expenses and other items, this purchase price equates to an amount that is preliminarily estimated to be 60c, in cash, for each ordinary share of Rosetta Genomics outstanding at closing.
Genoptix is a portfolio company of Ampersand Capital Partners and 1315 Capital.
Barrington analyst Michael Petusky downgraded Rosetta Genomics to Market Perform after the company announced that it has agreed to be acquired by Genoptix.
To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.
This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.